Decera Clinical Education Pharmacy Practice Podcast

Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D

Episode Summary

Drs Diana Isaacs and Joshua J. Neumiller summarize key information on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and the role of the pharmacist in caring for these patients.

Episode Notes

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:

• Overview of chronic kidney disease
• Guideline recommendations
• Evidence for finerenone
• Role of the pharmacist

Presenter:

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Vice Chair and Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences  
Washington State University
Spokane, Washington

Review the downloadable slideset and the full program at:
https://bit.ly/3wxNAod